BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9137464)

  • 1. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
    Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
    Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of ploidy and proliferation markers in renal cell carcinoma.
    Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
    Cancer; 1996 Jan; 77(1):164-71. PubMed ID: 8630925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma.
    Tannapfel A; Geissler F; Köckerling F; Katalinic A; Hauss J; Wittekind C
    J Pathol; 1999 Mar; 187(4):439-45. PubMed ID: 10398104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
    Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
    J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic significance of proliferation markers in hepatocellular carcinoma (HCC)].
    Ebelt J; Neid M; Tannapfel A; Witzigmann H; Hauss J; Köckerling F; Wittekind C
    Zentralbl Chir; 2000; 125(7):597-601. PubMed ID: 10960968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis, PCNA and p53 in hepatocellular carcinoma.
    Paiva C; Oshima CT; Lanzoni VP; Forones NM
    Hepatogastroenterology; 2002; 49(46):1058-61. PubMed ID: 12143201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic prognostic indicators for renal cell carcinoma.
    Delahunt B
    Semin Diagn Pathol; 1998 Feb; 15(1):68-76. PubMed ID: 9503507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
    Kramer BA; Gao X; Davis M; Hall M; Holzbeierlein J; Tawfik O
    J Am Coll Surg; 2005 Oct; 201(4):565-70. PubMed ID: 16183495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis.
    Cheville JC; Terrell RB; Cohen MB
    Mod Pathol; 1994 Sep; 7(7):794-800. PubMed ID: 7824516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
    Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
    Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
    Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma.
    Migita T; Oda Y; Naito S; Tsuneyoshi M
    Cancer; 2002 Feb; 94(4):973-9. PubMed ID: 11920465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
    Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
    Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma.
    Richter EN; Oevermann K; Buentig N; Storkel S; Dallmann I; Atzpodien J
    J Urol; 2002 Aug; 168(2):460-4. PubMed ID: 12131288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
    Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
    Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.